questions, inquiries, important questions, treatment, surgery, limb sparing surgery, pathology, radiology, best orthopedic oncologist, best sarcoma surgeon, orthopedic oncology, orthopedic tumors, musculoskeletal tumors, preparation for surgery, sarcoma, bone tumor, bone sarcoma, soft tissue tumor, soft tissue cancer, soft tissue sarcoma, pediatric sarcoma, pediatric cancer, surgical oncologist, chemotherapy, radiation, sarcoma treatment, sarcoma surgery, outcomes, recuperation from surgery, preparation for surgery, optimization for surgery. osteosarcoma, Ewing sarcoma, chondrosarcoma, fibrosarcoma, adamantinoma, pediatric bone sarcoma, liposarcoma, MFH, UPS, pleomorphic sarcoma, synovial sarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, shoulder tumor, knee tumor, hip tumor, thigh tumor, PVNS, giant cell tumor, chondroblastoma, osteoblastoma, enchondroma, osteochondroma

For an appointment call:
833-292-BONE (2663)


dr james c wittig, orthopedic oncologist, new york, new jersey

Dr. Robert Maki named Mount Sinai Chief of Pediatric Hematology/Oncology and Medical Director, Sarcoma Cancer Program, at The Tisch Cancer Institute.
New York, NY
December 14, 2010

Robert Maki, MD, PhD, a renowned sarcoma cancer researcher, will join The Mount Sinai Medical Center as the Chief of the Pediatric Hematology/Oncology Division , and Medical Director of the Sarcoma Cancer Program in The Tisch Cancer Institute. His appointment will begin in early 2011.

"As a leader in soft-tissue and bone sarcoma research, Dr. Maki has made significant contributions to understanding and targeting this highly complex tumor type," said Steven J. Burakoff, MD, Director of The Tisch Cancer Institute at The Mount Sinai Medical Center, Lillian and Henry M. Stratton Professor of Cancer Medicine, and Professor of Hematology/Oncology and Oncological Sciences, Mount Sinai School of Medicine. "We are pleased that he has joined Mount Sinai to further propel the Tisch Cancer Institute to the forefront of research and patient care."

Dr. Maki’s expertise in novel therapies for the treatment of soft-tissue and bone sarcomas, has led him to investigate new drugs to attack molecular targets for this rare and varied group of cancers. There are more than 50 types of soft-tissue and bone sarcomas, which arise from connective tissues. Dr. Maki is collaborating extensively with other oncologists who are researching this group of diseases. He is also interested in novel clinical trial designs and in translational laboratory research to identify new targets that will inform future clinical trials.

As The Tisch Cancer Institute’s Medical Director for the Sarcoma Cancer Program, Dr. Maki’s responsibilities will include the expansion of the basic and translational sarcoma cancer research programs. He will work closely with his colleagues in the Division of Hematology and Medical Oncology, and in the Department of Orthopaedics, to deliver personalized treatments to sarcoma patients and develop novel therapeutics in this population. This collaboration will offer comprehensive specialty care to adult and pediatric patients with sarcoma, and build a portfolio of translational clinical trials to improve the outcome of patients with this aggressive cancer.

Dr. Maki will also be instrumental in strengthening and expanding the breadth of the pediatric clinical program in Hematology/Oncology, focusing on soft tissue and bone sarcomas, adolescent cancer care, and transitioning pediatric cancer patients to adult care. He will also be responsible for developing basic and clinical/translational research programs aligned with institutional strengths and strategic priorities.

"As Chief of Pediatric Hematology/Oncology, Dr. Maki will provide the strategic vision needed to deliver exceptional patient care while broadening our pediatric clinical program," said Lisa M. Satlin, MD, Chair of the Department of Pediatrics. "We look forward to having someone of his caliber lead the division."

Dr. Maki is currently an Associate Professor of Medicine at the Weill Cornell Medical College, and Co-Director of the Adult Sarcoma Program at Memorial Sloan-Kettering Cancer Center. After undergraduate studies at Northwestern University, he received his PhD and MD degrees from Weill-Cornell Medical College. He completed a residency in internal medicine at the Brigham and Women's Hospital, and a fellowship in medical oncology at the Dana-Farber Cancer Institute, both in Boston, and was on staff at Dana-Farber before moving to Memorial Sloan-Kettering.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. U.S. News & World Report consistently ranks The Mount Sinai Hospital among the nation's best hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.

For more information, visit Follow us on Twitter @mountsinainyc.

Posted in: In the News
Actions: E-mail | Permalink |
GamepassTv World Cup 2022 Live Copyright 2014 by
   Website Translation Widget



rolex replica for sale